Conference Coverage
Consider heterogeneous experiences among veteran cohorts when treating PTSD
NEW YORK - Veterans are not a homogeneous group; cohort and other individual factors should be considered when treating PTSD.
Susan Lava-Parmele is a Staff Physician, Rebecca Rudquist is a Research Study Coordinator, Janeen Trembley, Tammy Butterick, and Ronald Bach are Research Health Scientists, all at the Minneapolis Veterans Affairs Health Care System in Minnesota. Nicole Baldwin is a Medical Student; Janeen Trembley is an Adjunct Assistant Professor; Tammy Butterick is an Adjunct Assistant Professor, Department of Food Science and Nutrition and a Graduate Faculty Member in the College of Food, Agriculture and Nutrition; and Ronald Bach is an Associate Professor, all at the University of Minnesota in Minneapolis.
Correspondence: Ronald R. Bach (ronald.bach@va.gov)
Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies.
The veterans participating in this QI survey had similar demographics, symptomology, and exposures as did those in other studies.1-7 Therefore, improvements based on their responses are likely applicable to the health care of veterans experiencing GWI-associated symptoms at other VA health care systems as well.
Veterans with GWI can lose significant functional capacity and productivity due to their symptoms. The symptoms are chronic and have afflicted many Gulf War veterans for nearly 3 decades. Furthermore, the prevalence of GWI in Gulf War veterans continues to increase.5-7 These facts testify to the enormous health-related quality-of-life impact of GWI.
Veterans who meet the Kansas case definition for GWI were not diagnosed or service connected in a uniform manner. Only 3 of the 30 veterans in this study were given a unifying diagnosis that connected their chronic illness to Gulf War deployment. Under current guidelines, Gulf War veterans are able to receive compensation for chronic symptoms in 3 ways: (1) compensation for chronic unexplained symptoms existing for ≥ 6 months that appeared during active duty in the Southwest Asia theater or by December 31, 2021, and are ≥ 10% disabling; (2) the 1995 Persian Gulf War Veterans’ Act recognizes 3 multisymptom illnesses for which veterans can be service connected: FM, CFS, and functional GI disorders, including IBS; and (3) expansion to include any CMI of unknown etiology is underway. A uniform diagnostic protocol based on biomarkers and updated understanding of disease pathology would be helpful.
Respondents shared experiences that demonstrated perceived gaps in HCP support or knowledge. Overall, more respondents found their HCPs supportive. Many of the reasons respondents found HCPs unsupportive related to acknowledgment of symptoms. Also, more respondents found that both VA and non-VA HCPs lacked knowledge about GWI symptoms. These findings further highlight the need for HCP education within the VA and in community-based care.
The treatments tried by respondents also highlight potential areas for improvement. Most of the treatments were for pain; therefore, more involvement with pain clinics and specialists could be helpful. Symptom-specific medications also are appropriate, although only one-third of patients reported use. While medications are not necessarily markers of quality care, the fact that many patients self-medicate or go without treatment suggests that access to care could be improved. In 2014, the VA and the US Department of Defense (DoD) released the “VA/DoD Clinical Practice Guideline for the Management of Chronic Multisymptom Illness,” which recommended treatments for the global disease and specific symptoms.15
Since then, GWI research points to inflammatory and metabolic disease mechanisms.11-14,16 As the underlying pathophysiology is further elucidated, practice guidelines will need to be updated to include anti-inflammatory and antioxidant treatments used in practice for GWI and similar chronic systemic illnesses (eg, CFS, FM, and IBS).17-19
Randomized control trials are needed to determine the efficacy of such medications for the treatment of GWI. As new results emerge, disseminating and updating evidence-based guidelines in a coordinated manner will be required for veterans to receive appropriate treatment. Veterans also seek alternative or nonpharmaceutical interventions, such as physical therapy and diet changes. Improving access to integrative medicine, physical therapy, nutritionists, and other practitioners also could optimize veterans’ health and function.
NEW YORK - Veterans are not a homogeneous group; cohort and other individual factors should be considered when treating PTSD.
Patients may exhibit posttraumatic stress disorder symptoms prior to the onset of dementia or uncover long quiescent symptoms of the disease,...
The My Life, My Story patient-centered program uses veterans’ personal narratives by veterans to create a strong connection between patients and...
Qualified veterans were no more likely to take advantage of health care services after the VA presumptive infectious disease determination...